Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335503 | 0.81 | KDM4E (0.44) | TP53HBBSMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL29781155 | 0.80 | ALDH1A1 (0.45) | KDM4EGRM2 | |
| SCHEMBL334640 | 0.78 | KDM4E (0.42) | TP53HBBSMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL11598636 | 0.74 | TP53 (0.56) | TP53HBBSMN1; SMN2KDM4EDHFR | |
| SCHEMBL3471790 | 0.74 | TP53 (0.56) | TP53HBBSMN1; SMN2DHFR | |
| SCHEMBL31717880 | 0.73 | GRM2 (0.52) | KDM4EPIK3CDGRM2NAAA | |
| SCHEMBL17599183 | 0.72 | SMN1; SMN2 (0.48) | TP53HBBSMN1; SMN2KDM4EDHFR | |
| SCHEMBL8593693 | 0.72 | — | — | |
| SCHEMBL23160605 | 0.71 | PRMT5 (0.47) | DHFR | |
| SCHEMBL23160686 | 0.71 | PRMT5 (0.47) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2193980-A | — | — | None | — | — | JP | disclosed |
| CN-105315614-B | Porefilling heat curing resin composition, solidfied material and the printed circuit board of printed circuit board | 太阳油墨（苏州）有限公司 | 2018-10-30 | — | — | CN | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-5073639-A | Reacting a 2-oxazolidinone and a 2-nitroimidazole in the presence of potassium or cesium carbonate and treating the resulting compound with a hydrophalic acid | WARNER-LAMBERT COMPANY (US) | 1991-12-17 | — | — | US | disclosed |
| US-5036096-A | Sensitizers used in radiation and chemotherapy treatment of tumors | WARNER-LAMBERT COMPANY (US) | 1991-07-30 | — | — | US | disclosed |
| US-5036089-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1991-07-30 | — | — | US | disclosed |
| US-4954515-A | RADIOSENSITIZING OR CHEMOSENSITIZING AGENTS IN THE TREATMENT OF HYPOXIC TUMOR CELLS | WARNER-LAMBERT COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| JP-H02193980-A | NEW METHOD FOR SYNTHESIS OF NITROIMIDAZOLE USEFUL AS RADIOSENSITIZING AGENT | WARNER LAMBERT CO | 1990-07-31 | — | — | JP | disclosed |
| EP-0375951-A1 | A new process for the synthesis of novel and known nitroimidazoles which are useful as sensitizing agents | WARNER-LAMBERT COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | TP53 3887/4885HBB 687/4885SMN1; SMN2 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.